{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:18:19Z","timestamp":1790504299653,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/pcan.2017.16","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T06:20:49Z","timestamp":1492496449000},"page":"339-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance"],"prefix":"10.1038","volume":"20","author":[{"given":"J J","family":"Tosoian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H D","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mamawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Landis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J I","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H B","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Sokoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C P","family":"Pavlovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"BFpcan201716_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrurol.2016.45","volume":"13","author":"JJ Tosoian","year":"2016","unstructured":"Tosoian JJ, Carter HB, Lepor A, Loeb S . Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol 2016; 13: 205\u2013215.","journal-title":"Nat Rev Urol"},{"key":"BFpcan201716_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R et al. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64: 876\u2013892.","journal-title":"Eur Urol"},{"key":"BFpcan201716_CR3","first-page":"5975","volume":"59","author":"MJ Bussemakers","year":"1999","unstructured":"Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975\u20135979.","journal-title":"Cancer Res"},{"key":"BFpcan201716_CR4","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","volume":"184","author":"SM Aubin","year":"2010","unstructured":"Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184: 1947\u20131952.","journal-title":"J Urol"},{"key":"BFpcan201716_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ucl.2015.08.003","volume":"43","author":"JJ Tosoian","year":"2016","unstructured":"Tosoian JJ, Ross AE, Sokoll LJ, Partin AW, Pavlovich CP . Urinary biomarkers for prostate cancer. Urol Clin North Am 2016; 43: 17\u201338.","journal-title":"Urol Clin North Am"},{"key":"BFpcan201716_CR6","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","volume":"32","author":"JT Wei","year":"2014","unstructured":"Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014; 32: 4066\u20134072.","journal-title":"J Clin Oncol"},{"key":"BFpcan201716_CR7","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-12-3283","volume":"19","author":"DW Lin","year":"2013","unstructured":"Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013; 19: 2442\u20132450.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201716_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.juro.2009.10.003","volume":"183","author":"JJ Tosoian","year":"2010","unstructured":"Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183: 534\u2013538.","journal-title":"J Urol"},{"key":"BFpcan201716_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","volume":"271","author":"JI Epstein","year":"1994","unstructured":"Epstein JI, Walsh PC, Carmichael M, Brendler CB . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368\u2013374.","journal-title":"JAMA"},{"key":"BFpcan201716_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/pros.21011","volume":"69","author":"MP van Gils","year":"2009","unstructured":"van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA . Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. Prostate 2009; 69: 1624\u20131634.","journal-title":"Prostate"},{"key":"BFpcan201716_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH . Random-effects models for longitudinal data. Biometrics 1982; 38: 963\u2013974.","journal-title":"Biometrics"},{"key":"BFpcan201716_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O","volume":"16","author":"DW Hosmer","year":"1997","unstructured":"Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S . A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997; 16: 965\u2013980.","journal-title":"Stat Med"},{"key":"BFpcan201716_CR13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.juro.2013.12.005","volume":"191","author":"KK Chevli","year":"2014","unstructured":"Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol 2014; 191: 1743\u20131748.","journal-title":"J Urol"},{"key":"BFpcan201716_CR14","doi-asserted-by":"publisher","first-page":"17767","DOI":"10.3390\/ijms140917767","volume":"14","author":"A Ruffion","year":"2013","unstructured":"Ruffion A, Devonec M, Champetier D, Decaussin-Petrucci M, Rodriguez-Lafrasse C, Paparel P et al. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci 2013; 14: 17767\u201317780.","journal-title":"Int J Mol Sci"},{"key":"BFpcan201716_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4103\/1008-682X.125390","volume":"16","author":"Y Luo","year":"2014","unstructured":"Luo Y, Gou X, Huang P, Mou C . The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl 2014; 16: 487\u2013492.","journal-title":"Asian J Androl"},{"key":"BFpcan201716_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","volume":"185","author":"SE Eggener","year":"2011","unstructured":"Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869\u2013875.","journal-title":"J Urol"},{"key":"BFpcan201716_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.eururo.2016.05.021","volume":"71","author":"TM Ma","year":"2017","unstructured":"Ma TM, Tosoian JJ, Schaeffer EM, Landis P, Wolf S, Macura KJ et al. The role of multiparametric magnetic resonance imaging\/ultrasound fusion biopsy in active surveillance. Eur Urol 2017; 71: 174\u2013180.","journal-title":"Eur Urol"},{"key":"BFpcan201716_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.juro.2013.09.029","volume":"191","author":"HD Patel","year":"2014","unstructured":"Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB . Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol 2014; 191: 629\u2013637.","journal-title":"J Urol"},{"key":"BFpcan201716_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamaoncol.2016.0170","volume":"2","author":"HD Patel","year":"2016","unstructured":"Patel HD, Chalfin HJ, Carter HB . Improving prostate cancer screening and diagnosis: health policy and biomarkers beyond PSA. JAMA Oncol 2016; 2: 867\u2013868.","journal-title":"JAMA Oncol"},{"key":"BFpcan201716_CR20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.urology.2006.10.022","volume":"68","author":"DJ Parekh","year":"2006","unstructured":"Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006; 68: 1152\u20131155.","journal-title":"Urology"},{"key":"BFpcan201716_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 2016; 70: 45\u201353.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201716","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pcan.2017.16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T17:12:51Z","timestamp":1648660371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFpcan201716"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2017.16","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]},"assertion":[{"value":"23 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}